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Dear Editor,  
Physicist and philosopher Ernst Mach said that a well-chosen word can economize thought [1]. 
However, when faced with multiple terms for naming an entity many people could get 
confused about meaning and semantics, then, becomes an issue. This could be the case for the 
inflated world of terms used for hypertension phenotypes, i.e., white coat hypertension and 
masked hypertension.  
The rationale for constructing new terms for variants of these phenotype conditions is 
that they could represent clinically different entities. For example, the condition called white 
coat hypertension is theoretically only possible for an untreated individual whose blood 
pressure (BP) is elevated in the office or clinic but normal under ambulatory blood pressure 
monitoring (ABPM). A treated hypertensive patient with the same diagnostic definition for 
clinic and ABPM-based BP as the untreated, could not appropriately be termed a white coat 
hypertensive. This is because he or she may well have been a sustained hypertensive subject 
before starting treatment (with both clinic and ambulatory BP elevated) whose ambulatory BP, 
but not their clinic BP, was controlled on treatment, thus, simulating white coat hypertension. 
That is the main reason why, increasingly, authors and guidelines often recommend saving the 
use of “white coat hypertension” for untreated individuals. This label was proposed by 
Pickering and colleagues at the beginning of the 1980s [2], paralleling the “alarm reaction” 
(transient increase in BP during doctor´s visit) elegantly demonstrated by Mancia and 
colleagues in 1983 [3]. 
The term “white coat hypertension” is probably a misnomer and a misconception, as 
Mancia and Zanchetti have argued [4], since it does not necessarily reflect, or at most partially, 
an alerting reaction or white coat effect and it is not purely emotional in nature. However, as 
Zanchetti ironically commented, the acceptance of a more descriptive name for this condition 
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(e.g., isolated clinic hypertension) is a lost war [5], and the term is so commonly used that we 
probably do right in using it as well.  
Thus, new names have been proposed for treated white coat hypertensive patients such 
as pseudoresistant hypertension by Myers, false resistant hypertension or treated normalized 
hypertension due to white coat effect by Franklin and colleagues, and office resistance by 
Pickering [6-8]. Some of these terms have been recently incorporated in guidelines [9,10]. 
Almost all these terms recognize the existence of BP control resistance in the clinic in the 
presence of  a good control of ambulatory BP under treatment. Further, Ben-Dov and 
colleagues used the term “white coat uncontrolled hypertension” for treated patients with clinic 
BP elevated alone [11], mimicking white coat hypertension. We now propose to summarize 
this term as WUCH (White coat UnControlled Hypertension) which we think has phonetic and 
mnemonic advantages, in the context of the other acronyms we propose below for the other two 
phenotypes.  
Regarding the condition of normal clinic BP but elevated ambulatory BP in untreated 
individuals, Pickering and colleagues introduced the term masked hypertension [12]. We 
proposed the acronym MUCH (Masked UnControlled Hypertension) [13] for masked 
hypertension in treated patients. These patients are treated hypertensive, thus their hypertension 
is not masked, instead what is masked is the lack of ambulatory BP control despite seemingly 
well-controlled clinic BP.  
Lastly, there are two other conditions at play in the cross-classification of hypertension 
status according to clinic BP and ABPM, one where both clinic and ambulatory BP are elevated 
and the other where both are normal. In untreated individuals, the commonly used terms 
sustained hypertension and normotension seem adequate for these two conditions, respectively. 
However, in treated patients we may well use the term true uncontrolled hypertension for those 
patients who are uncontrolled at both in-office and out-of-office settings. Here we propose the 
acronym TUCH (True UnControlled Hypertension), phonetically consonant with the previous 
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acronyms WUCH and MUCH and thus supposedly easier to recall. As seen, these terms share 
the common last name “uncontrolled hypertension” (UCH) preceded by the words white coat 
(W), masked (M), or true (T), respectively, in a coherent fashion to easily recall these names 
even without acronyms. Finally, for people with both clinic and ambulatory BP controlled 
under treatment the term controlled hypertension could apply.  
Far from adding noise in terminology by creating neologisms or abbreviating already 
existing terms, we aim at introducing user´s friendly acronyms for treated hypertension 
phenotypes that potentially improve communication among clinicians and researchers while 
economizing thought and time. Time will have the last word.  
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